Breaks Categories: Stock Spotlights

FridayAug 07, 2020 1:23 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Marks Milestone in Applying AI to Find New Targets for Treatment, Diagnostics

Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis and working with distributor US Biological Corporation, has accomplished a major achievement. Recently, the company announced its first-ever commercial order of a novel ovarian cancer cell culture media for cancer cells collected from patient-derived samples (“PDx”) (http://ibn.fm/2xwl6). An article discussing this quotes Richard Gabriel of TumorGenesis, who states, “Capturing and culturing and then being able to study ovarian cancer cell types has always been limited by the ability to grow reproducible cultures that reflect what is in the patient. We now have isolated and grown 25 ovarian cancer cell types, 11 of that…

Continue Reading

ThursdayJul 30, 2020 2:02 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Integrate Proprietary Database with CoRE to Drive Drug Discovery, Development

Predictive Oncology (NASDAQ: POAI) has completed a strategic move to accelerate commercialization of its proprietary artificial intelligence “AI”-driven drug discovery and development. A recent article discussing Predictive Oncology’s recent acquisition of Quantitative Medicine (“QM”), a biomedical analytics and computational biology company, quotes POAI CEO Dr. Carl Schwartz, where he states, “This acquisition will enable us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing. Integrating QM’s proven machine-learning platform, CoRE, with our proprietary database of drug response and…

Continue Reading

MondayJul 27, 2020 2:30 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Deliver Best-In-Class RPM Solution Across the United Kingdom and Ireland

DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, will begin serving Europeans with its health-monitoring solution through a strategic partnership with Williams Medical. Under the partnership, the DarioHealth Remote Patient Monitoring (“RPM”) digital therapeutics platform will be made available to healthcare professionals across the United Kingdom and Ireland. A recent article quotes DarioHealth COO Dror Bacher on this move, where Bacher states, “We are very excited about this partnership between DarioHealth and Williams Medical as this aligns with our international growth initiative by offering our world-class RPM platform to physicians outside of the United…

Continue Reading

FridayJul 24, 2020 1:46 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Provides Standout Solution for Digital Diabetes Management

DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, was recently featured in a Data Bridge Market Research report. The piece highlighted DarioHealth’s advancements in digital diabetes management, a rapidly growing market expected to become the “next best thing” in the wake of the current coronavirus pandemic that has made it more difficult for patients to receive treatment. A recent article discussing the company’s standout solution reads, “With 4.9 stars on the Apple App Store and 11,000 reviews, Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app…

Continue Reading

WednesdayJul 22, 2020 1:19 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) on ‘Cash Runway’ to Fund Key Milestones

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is on a well-funded path to move forward with its goals. A recent article discussing this quotes POAI CEO Dr. Carl Schwartz, who states, “[POAI] improved our liquidity position and streamlined our capital structure with the conversion of a $2.1 million convertible note, previously held by me, to newly issued equity. This action demonstrates my confidence in the commercial viability of our work, and when combined with the additional capital we raised through an equity offering, provides us with the cash…

Continue Reading

ThursdayJul 16, 2020 12:32 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. Arms Clinicians, Targets Global OSA Market with Alternative Solutions

Vivos Therapeutics, an emerging leader in the treatment of obstructive sleep apnea (“OSA”), is positioned to capitalize on the growing global OSA market, projected to reach $13.24 billion by 2027. The company’s unique approach is to arm clinicians in treating patients suffering from OSA. A recent article discussing this reads, “The company’s oral appliances have proven to be effective in more than 15,000 patients successfully treated worldwide by approximately 1,350 trained dentists. Vivos’ vision is to provide clinicians with the tools to provide the best alternative solution to treat OSA.” To view the full article, visit http://ibn.fm/ge0Jr About Vivos Therapeutics…

Continue Reading

TuesdayJul 14, 2020 11:45 am

BioMedNewsBreaks – Why DarioHealth Corp. (NASDAQ: DRIO) Is ‘One to Watch’

DarioHealth (NASDAQ: DRIO) is a pioneer in the global digital therapeutics market focused on delivering evidence-based interventions to people with chronic conditions. A recent article discussing DarioHealth reads, “Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.” To view the full article, visit http://ibn.fm/QtIUL About DarioHealth Corp. DarioHealth is a leading, global, digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality…

Continue Reading

FridayJul 10, 2020 1:50 pm

BioMedNewsBreaks – Vivos Therapeutics Inc.’s Innovative System Leverages Multidisciplinary Protocol in OSA Treatment

Vivos Therapeutics’ proprietary Vivos System(R) leverages a multidisciplinary treatment protocol comprised of comfortable oral devices and other therapies as needed. Over the course of treatment, typically ranging from 18 to 24 months, most patients experience an increased and enhanced upper airway with the purpose of reducing tissue obstructions causing obstructive sleep apnea (“OSA”). A recent article discussing this reads, “Vivos Therapeutics Inc. offers a new and superior alternative for treating obstructive sleep apnea, and the company believes its technology represents the most important breakthrough in OSA treatment since Continuous Positive Airway Pressure (‘CPAP’), which involves the use of special face…

Continue Reading

FridayJun 19, 2020 1:46 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. Develops Potential, Nonsurgical Solution for Obstructive Sleep Apnea

Vivos Therapeutics, an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), has developed a groundbreaking remedy that holds the potential to be a possible solution for the life-threatening condition. A recent article further discussing the company reads, “This innovative medical device technology company has created and patented a novel system to combat OSA caused by deficiencies and other tissue anomalies in craniofacial anatomy development — the root cause behind 98% of OSA cases. The Vivos System requires no surgery but is a multidisciplinary treatment protocol that consists of comfortable and customized oral devices.  Over the typical 18-to-24-month…

Continue Reading

WednesdayJun 10, 2020 12:53 pm

BioMedNewsBreaks – Why Vivos Therapeutics Inc. Is ‘One to Watch’

Vivos Therapeutics, an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), is on a mission to eliminate OSA using its revolutionary Vivos System(R), a clinical breakthrough in the treatment of sleep apnea caused by craniofacial anatomy development. An article discussing the company reads, “Designed to promote correct growth and development of the hard and soft tissues surrounding and compromising the oral cavity, nasal cavity, upper and lower jaws, and other tissues that comprise and shape the human airway. The system uses Pneumopedics(R), the natural process induced by Vivos biomimetic technology to widen and expand the patient’s airway,…

Continue Reading